Suppr超能文献

Intraperitoneal therapy in the management of ovarian carcinoma.

作者信息

Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadones L, Lewis J L

机构信息

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

出版信息

Yale J Biol Med. 1989 Jul-Aug;62(4):393-403.

PMID:2688324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2589079/
Abstract

The intraperitoneal administration of chemotherapeutic and biological agents as therapy of ovarian carcinoma is based on both theoretical considerations and experimental evaluations which suggest that tumor present in the cavity can be exposed to higher concentrations of certain antineoplastic drugs than can be accomplished if the agents are administered systemically. Recent clinical data have confirmed both the safety and pharmacokinetic advantage associated with this approach. Surgically defined responses have been observed in patients with small-volume residual refractory ovarian carcinoma treated with several single-agent and combination intraperitoneal therapeutic programs. While significant activity has been noted in this clinical setting, a clearly defined role for intraperitoneal treatment in the standard management of ovarian carcinoma remains to be determined.

摘要

相似文献

1
Intraperitoneal therapy in the management of ovarian carcinoma.
Yale J Biol Med. 1989 Jul-Aug;62(4):393-403.
2
Intraperitoneal chemotherapy for ovarian carcinoma.
Biomed Pharmacother. 1987;41(8):420-4.
3
Intraperitoneal chemotherapy in the management of ovarian cancer.
Semin Oncol. 1985 Sep;12(3 Suppl 4):75-80.
4
Nursing perspectives on intraperitoneal chemotherapy.
J Intraven Nurs. 1991 Sep-Oct;14(5):309-14.
5
[Second line chemotherapy of carcinoma of the ovary. Current approaches].
G Ital Oncol. 1989 Oct-Dec;9(4):121-4.
6
A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol. 1998 Dec;71(3):410-5. doi: 10.1006/gyno.1998.5206.
7
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Gynecol Oncol. 1999 Jul;74(1):48-52. doi: 10.1006/gyno.1999.5455.
8
Melphalan and cytarabine administered intraperitoneally as single agents and combination intraperitoneal chemotherapy with cisplatin and cytarabine.
Semin Oncol. 1985 Sep;12(3 Suppl 4):33-7.
9
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
J Clin Oncol. 1991 Feb;9(2):204-10. doi: 10.1200/JCO.1991.9.2.204.
10
[Intraperitoneal chemotherapy in ovarian carcinoma].
Harefuah. 2001 Sep;140(9):844-9, 894, 893.

引用本文的文献

1
Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research.
J Control Release. 2023 Sep;361:717-726. doi: 10.1016/j.jconrel.2023.08.017. Epub 2023 Aug 22.
2
Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.
AAPS J. 2015 Sep;17(5):1065-79. doi: 10.1208/s12248-015-9785-x. Epub 2015 Jun 19.
3
Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.
J Control Release. 2013 Dec 28;172(3):737-44. doi: 10.1016/j.jconrel.2013.09.011. Epub 2013 Sep 20.
4
Intraperitoneal therapy for peritoneal cancer.
Future Oncol. 2010 Oct;6(10):1625-41. doi: 10.2217/fon.10.100.
5
Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
Br J Cancer. 1996 Oct;74(7):1023-9. doi: 10.1038/bjc.1996.484.
6
Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
Pharm Res. 1993 Oct;10(10):1434-41. doi: 10.1023/a:1018963006703.
7
Clinical pharmacokinetics of carboplatin.
Clin Pharmacokinet. 1991 Oct;21(4):242-61. doi: 10.2165/00003088-199121040-00002.
8
Taxol: an important new drug in the management of epithelial ovarian cancer.
Yale J Biol Med. 1991 Nov-Dec;64(6):583-90.

本文引用的文献

1
Hemisulfur mustard in the palliation of patients with metastatic ovarian carcinoma.
Obstet Gynecol. 1959 Apr;13(4):383-93. doi: 10.1097/00006250-195904000-00001.
2
Use of nitrogen mustard in treatment of serous effusions of neoplastic origin.
J Am Med Assoc. 1955 Dec 31;159(18):1704-7. doi: 10.1001/jama.1955.02960350004002.
3
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Cancer Res. 1980 Mar;40(3):567-72.
4
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Cancer Res. 1981 Jan;41(1):55-9.
5
Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy.
Cancer Res. 1980 Oct;40(10):3665-8.
6
Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro.
Cancer Res. 1981 Sep;41(9 Pt 1):3495-8.
7
Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas.
Med Pediatr Oncol. 1981;9(3):245-50. doi: 10.1002/mpo.2950090307.
8
Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer.
Cancer Res. 1982 Oct;42(10):4265-9.
9
Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter.
Surg Gynecol Obstet. 1982 Jun;154(6):858-62.
10
Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.
J Clin Invest. 1981 Apr;67(4):1161-70. doi: 10.1172/jci110130.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验